Contaminant hepatotoxins as culprits for kava hepatotoxicity - Fact or fiction?

Phytotherapy Research

Volumn 27, Issue 3, 2013, Pages 472-474

  Teschke, Rolf ^a   Sarris, Jerome ^b,c   Lebot, Vincent ^d  

^a Department of Internal Medicine II   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^d CIRAD   (France)

Author keywords

contaminant hepatotoxins; kava; kava constituents; kava hepatotoxicity; mould hepatotoxins

Indexed keywords

ALKALINE PHOSPHATASE; FLAVOKAVAIN B; GAMMA GLUTAMYLTRANSFERASE; KAVA; MYCOTOXIN; PIPERMETHYSTINE; TOXIN; UNCLASSIFIED DRUG;

AFLATOXICOSIS; ARTICLE; CHOLESTASIS; CLINICAL ASSESSMENT; CYTOTOXICITY; DISEASE PREDISPOSITION; ENZYME INDUCTION; HISTOPATHOLOGY; HUMAN; LIVER NECROSIS; LIVER TOXICITY; MALNUTRITION; MOULD; NONHUMAN;

DRUG CONTAMINATION; DRUG-INDUCED LIVER INJURY; HUMANS; KAVA; PLANT EXTRACTS;

PIPER METHYSTICUM;

EID: 84874931332     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4729     Document Type: Article

References (28)

1. Anke J, Ramzan I,. 2004. Kava hepatotoxicity: Are we any closer to the truth? Planta Med 70: 193-196. (Pubitemid 38445182)
2. Berry CL,. 1988. Review article: The pathology of mycotoxins. J Pathol 154: 301-311.
3. Krishnamachari KAVR, Bhat RV, Nagarajan V, Tilak TBG,. 1975. Hepatitis due to aflatoxicosis: An outbreak in Western India. Lancet I: 1061-1063.
4. Lasme P, Davrieux F, Montet D, Lebot V,. 2008. Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in Vanuatu. J Agric Food Chem 56: 4976-4981. (Pubitemid 352039092)
5. Lebot V,. 2006. The quality of kava consumed in the South Pacific. HerbalGram 71: 34-37.
6. Lebot V, Lévesque J,. 1989. The origin and distribution of kava (Piper methysticum Forst. F. Piperaceae): A phytochemical approach. Allertonia 5: 223-281.
7. Lebot V, Lévesque J,. 1996. Evidence for conspecificity of Piper methysticum Forst. f. and P. wichmannii C. DC. Biochem System Ecol 24: 775-782. (Pubitemid 126649767)
8. Lebot V, Merlin M, Lindstrom L,. 1997. Kava, the Pacific elixir. Yale University Press: New Haven.
9. Li XZ, Ramzan I,. 2010. Role of ethanol in kava hepatotoxicity. Phytother Res 24: 475-480
10. Ngindu A, Johnson BK, Kenya PR, et al. 1982. Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet II: 1346-1348. (Pubitemid 12119225)
11. Olsen L, Grillo M, Skonberg C,. 2011. Constituents in kava extracts potentially involved in hepatotoxicity-A review. Chem Res Toxicol 24: 992-1002.
12. Peraica M, Radic B, Lucic A, Pavlovic M,. 1999. Toxic effects of mycotoxins in humans. Bull World Health Organ 77: 754-766. (Pubitemid 29477027)
13. Rowe A, Ramzan I,. 2012. Letter to the Editor: Are mould hepatotoxins responsible for kava hepatotoxicity? Phytother Res, in press. DOI: 10.1002/ptr.4620.
14. Sarris J, Adams J, Kavanagh D,. 2010. An explorative qualitative analysis of participants' experience of using kava versus placebo in an RCT. Aust J Med Herbalism 22: 12-16.
15. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G,. 2009. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 205: 399-407.
16. Schmidt M,. 2007. Quality criteria for kava. HerbalGram 73: 45-49.
17. Teschke R,. 2010a. Kava hepatotoxicity-a clinical review. Ann Hepatol 9: 251-265.
18. Teschke R,. 2010b. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 30: 1270-1279.
19. Teschke R, Lebot V,. 2011. Proposal for a Kava Quality Standardization Code. Food Chem Toxicol 49: 2503-2516.
20. Teschke R, Schulze J,. 2010. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Assoc 304: 2174-2175.
21. Teschke R, Qiu SX, Lebot V,. 2011a. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liv Dis 43: 676-681.
22. Teschke R, Qiu SX, Xuan TD, Lebot V,. 2011b. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res 25: 1262-1274.
23. Teschke R, Sarris J, Glass X, Schulze J,. 2011c. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol 71: 445-448.
24. Teschke R, Sarris J, Lebot V,. 2011d. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine 18: 96-103.
25. Teschke R, Sarris J, Schweitzer I,. 2012. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 73: 170-174.
26. TGA (Therapeutic Goods Administration). 2005. Australian Government, Department of Health and Aging, Kava fact sheet, April 2005. Web page last updated February 23, 2011. Available at: http://www.tga.gov.au/safety/alerts- medicine-kava-050421.htm. Accessed April 8, 2012.
27. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D,. 2004. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80: 1106-1122. (Pubitemid 41350669)
28. Zimmerman HJ,. 1999. Hepatotoxicity. Lippincott Williams & Wilkins: Philadelphia.